Research with human participants

Overview of medical research in the Netherlands

NKI-AVL Biobank (for blood and blood products)

Published:
Last updated:

-

Download: PDF | XML
Ethical review
Approved WMO
Status
Pending
Health condition type
Other condition
Study type
Observational invasive

ID

NL-OMON32651

Source

ToetsingOnline

Brief title

NKI-AVL Biobank

Condition

  • Other condition
  • Miscellaneous and site unspecified neoplasms malignant and unspecified

Synonym

cancer

Health condition

kanker- en therapie-gerelateerde aandoeningen

Research involving

Human

Sponsors and support

Primary sponsor :
Nederlands Kanker Instituut
Source(s) of monetary or material Support :
Ministerie van OC&W

Intervention

Keyword :
biobank, blood, DNA, serum

Outcome measures

Primary outcome

-

Secondary outcome

-

Background summary

-

Study objective

-

Study design

-

Study burden and risks

-

Public
Nederlands Kanker Instituut

Plesmanlaan 121
1066 CX
NL
Scientific
Nederlands Kanker Instituut

Plesmanlaan 121
1066 CX
NL

Listed location countries

Netherlands

Age

Adults (18-64 years)
Elderly (65 years and older)

Inclusion criteria

- newly diagnosed patient, selected tumor types
- or healthy volunteer visiting NKI-AVL

Exclusion criteria

-

Design

Study type :
Observational invasive
Intervention model
:
Other
Allocation :
Non-randomized controlled trial
Masking :
Open (masking not used)
Control :
Active
Primary purpose :
Other

Recruitment

NL
Recruitment status
:
Pending
Start date (anticipated) :
Enrollment :
50000
Type :
Anticipated

Approved WMO
Application type :
First submission
Review commission :
PTC Stichting het Nederlands Kanker Instituut - Antoni van Leeuwenhoekziekenhuis (Amsterdam)

Followed up by the following (possibly more current) registration

No registrations found.

Other (possibly less up-to-date) registrations in this register

No registrations found.

In other registers

Register ID
CCMO NL29873.031.09